Table 1.
CD4 Cell Count at Virologic Failure or at Switch to Second-Line ART, Overall and by Country, in Sub-Saharan Africa
| Characteristic | Participants Identified at Time of Virologic Failure | Participants Identified at 2nd-Line ART Switch | ||||
|---|---|---|---|---|---|---|
| No. of Articles (%) | Sample Size, No. (%) |
a
CD4 Cell Count, Cells/µL, Mean (95% CI) |
No. of Articles (%) | Sample Size, No. (%) |
a CD4 Cell Count, Cells/µL, Mean (95% CI) | |
| Total sample | 26 (100) | 9883 (100) | 213 (181 to 246) | 10 (100) | 4306 (100) | 158 (128 to 188) |
| Country of origin | ||||||
| South Africa | 7 (27) | 8465 (86) | 178 (138 to 219) |
3 (30) | 1529 (36) |
187 (170 to 204) |
| Cameroon | 2 (7.7) | 175 (2) |
131 (71 to 191) | - | - | - |
| Ethiopia | 1 (3.8) | 15 (0.2) | 387 (299 to 426) | - | - | - |
| Guinea-Bissau | 1 (3.8) | 36 (0.4) | 217 (157 to 310) | - | - | - |
| Kenya | 2 (7.7) | 89 (0.9) |
117 (91 to 144) | - | - | - |
| Lesotho | 1 (3.8) | 138 (1) | 351 (182 to 520) | - | - | - |
| Mali | 1 (3.8) | 84 (0.8) | 292 (6 to 1319) | - | - | - |
| Malawi | - | - | - | 1 (10) | 106 (2) | 65 (22 to 173) |
| Mozambique | 1 (3.8) | 48 (0.5) | 234 (113 to 322) | - | - | - |
| Nigeria | - | - | - | 4 (40) | 871 (20) |
144 (70 to 218) |
| Senegal | 1 (3.8) | 79 (0.8) | 340 (178 to 481) | - | - | - |
| Swaziland | 1 (3.8) | 78 (0.8) | 254 (167 to 394) | - | - | - |
| Tanzania | 1 (3.8) | 63 (0.6) | 334 (134 to 549) | 1 (10) | 1760 (41) | 205b |
| Uganda | 4 (15) | 317 (3) |
223 (154 to 292) | 1 (10) | 40 (1) | 108 (43 to 205) |
| Zambia | 2 (7.7) | 233 (2) | 129 (116 to 142) |
- | - | - |
| Study included multiple countriesa | 1 (3.8) | 63 (0.6) | 232 (128 to 324) | - | - | - |
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range.
For countries with >1 study, mean CD4 cell count and 95% CI were reported; for countries with 1 study, median CD4 cell count and IQR are shown as reported in the publication.
This study reported mean CD4 and standard deviation only.